Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology (NASDAQ:CSBR) will present eight poster studies at the AACR Annual Meeting April 17-22, 2026, in San Diego.
Presentations cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs, and CAR-T, showing how patient-derived models and integrated molecular and functional data aim to reduce translational risk and guide development decisions.
Champions Oncology (Nasdaq:CSBR) appointed Brian Alexander, MD, MPH, to its Board of Directors on March 30, 2026, to advance its data-driven translational oncology strategy. His experience in oncology, data science, and drug development supports Champions' effort to connect patient-derived tumor models with molecular and clinical datasets.
The company intends to use advanced analytics and AI to deepen disease insights, accelerate discovery, and improve translational R&D outcomes by linking PDX tumor models with multi-omic and patient data.
Champions Oncology (Nasdaq:CSBR) reported Q3 fiscal 2026 total revenue of $16.6 million (record study service revenue, +32% year-over-year excluding a prior $4.5M data license). Adjusted EBITDA was $574,000 and GAAP loss from operations was about $276,000. Cash was approximately $7.1 million with no debt.
Costs and operating expenses rose 34.3% year-over-year, driven by outsourced lab services and investments in the data platform and commercial team; management expects margin improvement as radiolabeling moves in-house.
Champions Oncology (NYSE: CSBR) will report third-quarter results for the period ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call the same day at 4:30 P.M. EDT (1:30 P.M. PDT).
Dial-in details: Domestic 888-506-0062, International 973-528-0011, access code 957548. A replay is available for 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 53731, or via the investors section of the company website.
Champions Oncology (Nasdaq:CSBR) reported record quarterly service revenue of $15.0 million for Q2 FY2026 (period ended Oct 31, 2025), up 11.5% year‑over‑year, and oncology services profit of $7.8 million with a margin of 52% (vs 45% prior year). Adjusted EBITDA was $843,000 and net income was $237,000 for the quarter. Year‑to‑date revenue was $29.0 million (+5.4%) with adjusted EBITDA of $962,000. Cash on hand was approximately $8.5 million and the company reported no debt. Management emphasized investment in its data platform and targeted sales/IT hires while expecting positive adjusted EBITDA for the full fiscal year.
Champions Oncology (NASDAQ:CSBR) will report financial and operational results for the second quarter ended October 31, 2025 on Monday, December 15, 2025 after market close.
The company will host a conference call the same day at 4:30 P.M. EST (1:30 P.M. PST). Domestic dial-in: 888-506-0062; International: 973-528-0011; access code: 691139.
A replay will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) with passcode 53331, or via the company's investor website within 72 hours.
Champions Oncology (NASDAQ:CSBR) reported Q1 FY2026 financial results with revenue of $14.0 million, slightly down from $14.1 million in the same period last year. The quarter saw a 3% decline in service revenue but was partially offset by increased data license revenue.
The company reported an operating loss of $527,000 compared to an income of $1.3 million in Q1 FY2025. Adjusted EBITDA was $59,000, down from $2.0 million year-over-year. Gross margin decreased to 43% from 50% due to higher outsourced lab services costs.
Notable developments include the appointment of Rob Brainin as CEO and a strong balance sheet with $10.3 million in cash and no debt. The company expects continued topline expansion and margin improvement driven by services pipeline and growing data offerings demand.
Champions Oncology (NASDAQ:CSBR) reported its Q1 FY2026 financial results with revenue of $14.0 million, slightly down from $14.1 million in the same period last year. The quarter was marked by the appointment of Rob Brainin as the new CEO and delivered an Adjusted EBITDA of $60,000.
The company experienced a 3% decline in service revenue but saw an increase in data license revenue. Operating expenses rose to $14.5 million, up 14.1% year-over-year, resulting in an operating loss of $527,000. Gross margin decreased to 43% from 50% in the prior year. The company maintains a strong financial position with $10.3 million in cash and no debt.
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its first quarter fiscal 2025 financial results announcement for Monday, September 15, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 261008 or listen to the replay within 72 hours through the company's website or by phone using passcode 52943.
Champions Oncology (NASDAQ:CSBR) reported strong financial results for fiscal year 2025, achieving record annual revenue of $57 million, representing a 14% year-over-year increase. The company demonstrated significant profitability improvements with net income of $4.6 million and adjusted EBITDA income of $7.1 million, compared to an adjusted EBITDA loss in the previous year.
Key highlights include the successful launch of a high-margin data business generating $4.7 million in data license revenue, improved gross margins reaching 50% (up from 41%), and a strong cash position of $9.8 million with no debt. However, Q4 showed some challenges with revenue declining 12% to $12.3 million and an adjusted EBITDA loss of $1.2 million.